<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604654</url>
  </required_header>
  <id_info>
    <org_study_id>SWYY-YQTLKL</org_study_id>
    <nct_id>NCT02604654</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Yiqitongluo Granule for Stroke</brief_title>
  <official_title>Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yi Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shineway Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the prospective study is to evaluate the effectiveness and safety of
      Yiqitongluo granule in the treatment of stroke with qi-deficiency and blood-stasis in more
      than sixy hospitals all over China.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Yiqitongluo for stroke measured by laboratory index</measure>
    <time_frame>change from baseline laboratory index at 28(±7) days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Yiqitongluo for stroke with mRS</measure>
    <time_frame>90(±7) days</time_frame>
    <description>mRS: modified Rankin Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Yiqitongluo for stroke with syndrome of traditional Chinese medicine</measure>
    <time_frame>28(±7) days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Yiqitongluo for stroke with NIHSS</measure>
    <time_frame>28(±7) days</time_frame>
    <description>NIHSS: the NIH stroke scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Yiqitongluo for stroke with BI</measure>
    <time_frame>28(±7) days</time_frame>
    <description>BI: Barthel Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Yiqitongluo for stroke with EQ-5D</measure>
    <time_frame>28(±7) days</time_frame>
    <description>The EQ-5D-3L essentially consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Yiqitongluo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yiqitongluo granule</intervention_name>
    <description>administered after dissolved</description>
    <arm_group_label>Yiqitongluo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild and moderate ischemic stroke patient with 4-25 NIHSS score

          -  stable patients within 1 week to 3 months

          -  sign informed consent before study

        Exclusion Criteria:

          -  CT shows cerebral hemorrhage disease: such as hemorrhagic stroke, epidural hematoma,
             intracranial hematoma, ventricular hemorrhage, and subarachnoid hemorrhage

          -  severe disturbance of consciousness

          -  dysphagia

          -  TIA

          -  hemorrhagic diathesis

          -  patient with malignant tumor whose expected lifetime is less than 3 months

          -  allergic constitution

          -  gestation period, lactation period, woman with the possibility or plan of pregnancy

          -  those who participated in other clinical trials within 3 months or taking part in
             other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Yang</last_name>
    <role>Study Chair</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhenni Guo</last_name>
    <role>Study Director</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Yi Yang</investigator_full_name>
    <investigator_title>Associated Dean of First Hospital of Jilin University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

